Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs

The BIOS21 Virtual summit is no longer accessible; stay tuned for the BIOS22 Virtual summit programme

https://www.medicinesforeurope.com/events/